(Reuters) – Pfizer will price its COVID-19 drug Paxlovid at nearly $1,400 for a five-day course when it begins the commercial sales later this year, according to the Wall Street Journal on Wednesday.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Shailesh Kuber)
